Aurora Cannabis
Canadian LP with medical and recreational operations in Canada and international medical cannabis markets.
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
The model outputs a Neutral rating for Aurora Cannabis, scoring 56/100 at conviction 2 of 5. Weights are locked at 35 percent fundamentals, 25 percent regulatory, 25 percent market, and 15 percent editorial, and each pillar is broken out for direct review. The regulatory pillar contributes the largest share at 88, pulling the composite into the middle of the band. Opposite that, editorial prints only 30, and is what keeps the rating anchored where it is.
Pillar-level, the record reads as reported revenue growth of 5.1 percent year over year, an operating margin of -26.4 percent, a filing cadence of 8 regulator events in the trailing 90 days. Each of those data points tethers the Neutral conclusion to observable evidence. Inputs are limited to primary regulatory filings, licensed fundamentals data, and institutional pricing feeds, plus a density read from CIN newsroom coverage. The rating enables direct comparison across the 336 tickers in the CIN coverage universe on a consistent, deterministic basis, and refreshes on a scheduled cadence tied to the primary-source ingest cycle.
Watch the regulatory pillar, which drives 88 of the composite. Continued filing cadence at or above the trailing 90-day pace, matched with a clean enforcement record, would justify moving toward the upper band edge.
- Headquarters
- 2207 90B STREET SW, EDMONTON, A0, T6X 1V8
- Phone
- 604-362-5207
- CEO
- Miguel Ma***n
- CFO
- Simona Ki***g
- SEC CIK
- 1683541
- Website
- Company website
- Market cap
- $167.9M
- Enterprise value
- $102.9M
- Price to book
- 0.46
- Price to sales
- 0.52
- EV / EBITDA
- 15.32
- Revenue (TTM)
- $320.6M
- Gross profit (TTM)
- $136.7M
- EBITDA
- $-33.0M
- Operating margin
- -26.4%
- Profit margin
- -42.4%
- Rev growth YoY
- 5.1%
- Return on equity
- -10.5%
- Return on assets
- -4.0%
- EPS (TTM)
- $-0.73
- EPS est. current year
- $-0.01
- Wall St. target price
- $6.23
- Shares outstanding
- 61.9M
- Insider ownership
- 1.3%
- Institutional ownership
- 9.7%
- Beta
- 1.35
- Full-time employees
- 1,028
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Filing portal
- SEDAR+
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for Aurora Cannabis (ACB)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Aurora Cannabis (ACB), a cannabis-sector equity listed on NYSE in the Canadian LP category. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Avoid / Capital Risk. Multiple flags: deep drawdown. (0 bullish signals, 3 bearish signals.)
Canadian LP with medical and recreational operations in Canada and international medical cannabis markets.
Latest price: $2.79 (-1.41%) on NYSE.
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for ACB are maintained by Cannabis Investor News and refreshed throughout the trading day.